OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to live 10 years longer than what it calls a healthy human lifespan.
Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin studies this year.
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission ...
OpenAI teamed up with Retro Biosciences to build a machine learning model focused on generating new proteins. The new model, called GPT-4b, is a custom version of OpenAI’s GPT-4o model built ...
Retro Biosciences, a startup that aims to use AI to aid in drug development, is reportedly raising $1 billion to support its research, with investors including OpenAI, which has previously backed ...
OpenAI says it trained a new AI model called GPT-4b micro with Retro Biosciences, a longevity science startup trying to extend the human lifespan by 10 ...
OpenAI’s new model, called GPT-4b micro, was trained to suggest ways to re-engineer the protein factors to increase their ...
The race to increase human life span through biotech just got tighter. Retro Biosciences, the AI-powered company whose mission is to develop therapies that reverse age-related disease, has just ...
OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to live 10 years longer than what it calls a healthy human lifespan. Now, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results